China recently inaugurated its first-ever biopharmaceutical pilot industrial park, the Guangdong-Hong Kong-Macao Greater Bay Area Biosafety Innovation Port, in Guangzhou's Huangpu district.
This landmark project is committed to bolstering biosafety in technological processes, creating a cutting-edge bioscience innovation hub, and catalyzing the industrialization of scientific achievements. All of which will drive Guangzhou to become an international nexus for technological innovation.
Currently, Huangpu is home to over 3,000 biopharmaceutical companies.
The Guangdong-Hong Kong-Macao Greater Bay Area Biosafety Innovation Port.